Intelligent Bio Solutions Inc.

NasdaqCM:INBS Stock Report

Market Cap: US$6.3m

Intelligent Bio Solutions Management

Management criteria checks 2/4

Intelligent Bio Solutions' CEO is Harry Simeonidis, appointed in Oct 2022, has a tenure of 3.58 years. total yearly compensation is $482.67K, comprised of 75.9% salary and 24.1% bonuses, including company stock and options. directly owns 1.44% of the company’s shares, worth $91.53K. The average tenure of the management team and the board of directors is 1.5 years and 4.7 years respectively.

Key information

Harry Simeonidis

Chief executive officer

US$482.7k

Total compensation

CEO salary percentage75.88%
CEO tenure3.6yrs
CEO ownership1.4%
Management average tenure1.5yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Analysis Article • Jun 18

The Future of Drug Testing? Fingerprint Tech From Intelligent Bio Solutions (NASDAQ:INBS) Shows Serious Promise

Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require urine cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
Seeking Alpha • Oct 04

GBS acquires Intelligent Fingerprinting in all-stock deal

GBS (NASDAQ:GBS) said Tuesday it acquired Intelligent Fingerprinting (IFP), expanding the GBS platform of rapid, non-invasive diagnostic testing technologies and its geographical reach. GBS also began the process of changing its corporate name. GBS issued ~3M shares and ~2.4M series C convertible preferred shares to IFP shareholders. Up to 1.6M preferred shares have been reserved for issuance to IFP's shareholders and lenders. Each preferred share is convertible into three GBS shares. Former IFP shareholders entered into a 12-month lock-up agreement on sales of GBS shares and preferred stock issued under the deal. Former majority IFP shareholders have the right to name two board members to GBS' board. With the acquisition, GBS gains access to IFP's product portfolio, current customer base, and manufacturing facility in the U.K. - which complements GBS' development of its own facility at the University of Newcastle, Australia. GBS in Jun. announced an exclusive deal to acquire IFP.
Seeking Alpha • Aug 31

GBS GAAP EPS of -$0.57, revenue of $0.44M

GBS press release (NASDAQ:GBS): FY GAAP EPS of -$0.57. Revenue of $0.44M (-77.8% Y/Y). As of June 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $8.2 million, compared to approximately $12.6 million on June 30, 2021.
Seeking Alpha • Aug 31

GBS Inc.: Can Its Technology Come Through?

GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets. GBS currently trades at around $3, which is an attractive entry point for investors. However - The high technological risk associated with its technology outweighs the low entry point. Technological Risk mainly stems from the fact that scientific literature disagrees over the reliability and accuracy of using saliva as a diagnostic medium.
Seeking Alpha • Aug 09

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

GBS Inc. is a developer of pioneering diagnostic platform adaptable to large unmet markets with multiple applications and indications. GBS has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company’s lead products are saliva glucose test and saliva SARS-CoV-2 antibody test.
Analysis Article • Jul 29

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Harry Simeonidis's remuneration changed compared to Intelligent Bio Solutions's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025n/an/a

-US$11m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025US$483kUS$366k

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024n/an/a

-US$11m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024US$447kUS$293k

-US$10m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023n/an/a

-US$13m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023US$397kUS$276k

-US$11m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022n/an/a

-US$5m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022US$355kUS$250k

-US$8m

Mar 31 2022n/an/a

-US$7m

Dec 31 2021n/an/a

-US$9m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021US$351kUS$240k

-US$7m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020n/an/a

-US$4m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020US$207kUS$157k

-US$3m

Compensation vs Market: Harry's total compensation ($USD482.67K) is about average for companies of similar size in the US market ($USD624.15K).

Compensation vs Earnings: Harry's compensation has increased whilst the company is unprofitable.

CEO

Harry Simeonidis (57 yo)

3.6yrs
Tenure
US$482,671
Compensation

Mr. Harry Simeonidis serves as Chief Executive Officer of Intelligent Bio Solutions Inc. since October 2022 and serves as its President since October 26, 2022. He had been Non-Executive Director of FarmaFo...

Leadership Team

NamePositionTenureCompensationOwnership
Harry Simeonidis
President & CEO3.6yrsUS$482.67k1.44%
$ 91.5k
Spiro Sakiris
Chief Financial Officer7.1yrsUS$363.53k1.5%
$ 95.1k
Callistus Sequeira
Vice President of Global Quality & Operations1.5yrsno datano data
Doug Heath
Vice President of Global Sales1.5yrsno datano data
Anna Turkington
Vice President of Marketing1.5yrsno datano data
1.5yrs
Average Tenure

Experienced Management: INBS's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jonathan Hurd
Independent Director8.1yrsUS$51.25k0.21%
$ 13.3k
Stephen Boyages
Independent Chairman of the Board5.8yrsUS$61.25k0.21%
$ 13.3k
Jason Isenberg
Independent Director3.6yrsUS$50.63kno data
Nicola Fraser
Independent Director1.9yrsUS$55.63k0.21%
$ 13.2k
4.7yrs
Average Tenure
53.5yo
Average Age

Experienced Board: INBS's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/27 13:53
End of Day Share Price 2026/05/27 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intelligent Bio Solutions Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey CohenLadenburg Thalmann & Company
John VandermostenZacks Small-Cap Research